Previous 10 | Next 10 |
The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this Read more ...
Gainers: Sonoma Pharmaceuticals (NASDAQ: SNOA ) +145% . More news on: Sonoma Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, Phio Pharmaceuticals Corp., Stocks on the move, , Read more ...
Will You Add these To Your List Of Penny Stocks? No matter if you trade penny stocks or look for ways of investing in penny stocks , there are certainly plenty of choices in the stock market today. But it’s important to remember that there are factors in play that can change your ini...
Sonoma Pharmaceuticals (NASDAQ: SNOA ) +162% on COVID-19 nod in Australia for disinfectant. More news on: Sonoma Pharmaceuticals, Inc., Phio Pharmaceuticals Corp., Adaptimmune Therapeutics plc, Stocks on the move, , Read more ...
Adaptimmune Thereapeutics (NASDAQ: ADAP ) shares soar after data from ADP-A2M4 Phase 1 trial was presented at at the American Society for Clinical Oncology ( OTC:ASCO ) Annual Meeting, showing durability and responses in synovial sarcoma. Data also indicated a new response in a lung ca...
- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy - - Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned ...
The road to success for most companies, biotechs included, is far from straight forward. Investors want to find those diamonds in the rough whose stock will substantially outperform, not just in the coming months but in the years ahead. One approach for achieving this requires discovering compan...
Adaptimmune Therapeutics plc (ADAP) Q1 2020 Earnings Conference Call May 14, 2020, 08:00 AM ET Company Participants Juli Miller - Director of IR Adrian Rawcliffe - CEO Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medical Officer Conference Call Participa...
Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP) Q1 2020 Earnings Call May 14, 2020 , 8:00 a.m. ET Operator Continue reading
Adaptimmune (NASDAQ: ADAP ): Q1 GAAP EPS of -$0.04 beats by $0.21 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...